Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?

被引：1

作者：

Calvo Romero, J. M. ^{[1
]}

机构：

[1] Hosp Ciudad Coria, Med Interna Serv, Coria, Caceres, Spain

来源：

REVISTA CLINICA ESPANOLA | 2011年 / 211卷 / 03期

关键词：

Dabigatran; Direct thrombin inhibitor; Vitamin K antagonist; Atrial fibrillation; INTERNATIONAL NORMALIZED RATIO; DIRECT THROMBIN INHIBITOR; ORAL ANTICOAGULATION; RISK STRATIFICATION; PREDICTING STROKE; GENERAL-PRACTICE; WARFARIN; THERAPY; MANAGEMENT; ETEXILATE;

D O I：

10.1016/j.rce.2010.12.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Patients with atrial fibrillation (AF) at risk of stroke are not always anticoagulated with vitamin K antagonists (VKA) despite lack of contraindication. Dabigatran, an oral direct thrombin inhibitor, is a new option with proven safety and effectiveness in these patients. The advantages of dabigatran are its more predictable response, obviating coagulation monitoring and possible lower frequency of bleedings. Its drawbacks are cost, lack of antidote and long-term data, frequency of dyspepsia and the twice daily dosage. (C) 2011 Elsevier Espana, S.L. All rights reserved.

引用

页码：142 / 146

页数：5

共 50 条

[21] Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran
Weimar, Christian
Hohnloser, Stefan H.
Eikelboom, John W.
Diener, Hans-Christoph
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2012, 12 (01) : 17 - 23
[22] Quality of life, adherence and satisfaction of patients with auricular fibrillation treated with dabigatran or vitamin K antagonists
Barrios, V.
Escobar, C.
Baron Esquivias, G.
Gomez Doblas, J. J.
Recalde del Vigo, E.
Segura Martinez, L.
Alvarez Garcia, P.
Alonso Valladares, F.
Toril Lopez, J.
Chopo Alcubilla, J. M.
REVISTA CLINICA ESPANOLA, 2019, 219 (06): : 285 - 292
[23] Benefit-Risk Assessment of Dabigatran in the Treatment of Stroke Prevention in Non-Valvular Atrial Fibrillation
dos Santos, Sascha Meyer
Harder, Sebastian
DRUG SAFETY, 2014, 37 (05) : 295 - 307
[24] New Anticoagulants (Dabigatran, Apixaban, Rivaroxaban) for Stroke Prevention in Atrial Fibrillation
Aguilar, Maria I.
Kuo, Ruth S.
Freeman, William D.
NEUROLOGIC CLINICS, 2013, 31 (03) : 659 - +
[25] Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study
Fauchier, Laurent
Blin, Patrick
Sacher, Frederic
Dureau-Pournin, Caroline
Bernard, Marie-Agnes
Lassalle, Regis
Droz-Perroteau, Cecile
Dallongeville, Jean
Moore, Nicholas
EUROPACE, 2020, 22 (02): : 205 - 215
[26] Spotlight on Dabigatran Etexilate in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
Karly P. Garnock-Jones
Drugs & Aging, 2011, 28 : 415 - 419
[27] Switching from vitamin K antagonist to dabigatran in atrial fibrillation: a differences according to dose
Vinding, Naja Emborg
Staerk, Laila
Gislason, Gunnar Hilmar
Torp-Pedersen, Christian
Bonde, Anders Nissen
Rorth, Rasmus
Lee, Christina J. Y.
Olesen, Jonas Bjerring
Kober, Lars
Fosbol, Emil Loldrup
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (01) : 20 - 30
[28] Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants
Caturano, Alfredo
Galiero, Raffaele
Pafundi, Pia Clara
MEDICINA-LITHUANIA, 2019, 55 (10):
[29] Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China
Dong, Shu-Jie
Wu, Bin
Zhai, Suo-Di
Zhang, Yan-Jun
Chu, Yun-Bo
Gupta, Parul
Li, Ya-Huei
CLINICAL THERAPEUTICS, 2020, 42 (01) : 144 - 156
[30] Stroke prevention in atrial fibrillation patients
Marinigh, Ricarda
Lip, Gregory Y. H.
Lane, Deirdre A.
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (14) : 2331 - 2350

← 1 2 3 4 5 →